Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Oct;15(10):911-912.
doi: 10.1111/1753-0407.13468. Epub 2023 Sep 20.

Should patient enrollment criteria for anti-VEGF phase III trials be reconsidered

Joel Hanhart  1   2 , Sohee Jeon  3 , Raimo Tuuminen  4   5   6
Affiliations
Clinical Trial

Should patient enrollment criteria for anti-VEGF phase III trials be reconsidered

Joel Hanhart et al. J Diabetes. 2023 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Joel Hanhart and Sohee Jeon have nothing to disclose. Raimo Tuuminen is a scientific advisor (advisory board, honoraria) to Alcon Laboratories, Inc., Allergan, Inc., and has received clinical trial support (study medicines) from Bayer AG and Laboratoires Théa.

References

    1. Bloomgarden Z. A diabetes update. J Diabetes. 2023;15(7):542‐544. doi:10.1111/1753-0407.13434 - DOI - PMC - PubMed
    1. Zafar S, Walder A, Virani S, et al. Systemic adverse events among patients with diabetes treated with intravitreal anti–vascular endothelial growth factor injections. JAMA Ophthalmol. 2023;141(7):658‐666. - PMC - PubMed
    1. VanderBeek BL. Difficulty in assessing the systemic adverse effects of intravitreal anti‐vascular endothelial growth factor therapy. JAMA Ophthalmol. 2023;141(7):666‐667. - PubMed
    1. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789‐801. - PubMed
    1. Korobelnik JF, Do DV, Schmidt‐Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247‐2254. - PubMed

Substances